Veeva：2024年解锁真正的KAM转换：您准备好了吗？（英文版）

The shift to specialty medicine is well underway: in 2023, nearly 80% of Food and Drug Administration (FDA) approval’s were for specialty drugs.1 As specialty medicine typically results in more complex patient journeys, life sciences organizations must engage differently with their most important customers when commercializing these high-value products. To succeed, companies have to move beyond the singleprescriber relationship and account for other stakeholders that shape clinical practice, inc